CancerVax Corporation (NASDAQ: CNVX), a biotechnology company focused on the research, development and commercialization of novel biological products for the treatment of cancer, today announced that the close of business on Monday, March 27, 2006, has been set as the record date for the determination of stockholders eligible to receive the proxy and vote at the annual meeting to be held to consider and approve the previously announced merger with Micromet AG, a corporation organized under the laws of Germany.
